// App-Quantinova.ai

: Trial in Progress: A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE ® Antibody Blinatumomab (Blincyto) and Vincristine Sulfate Liposomal Injection (Marqibo) in Adult Subjects with Relapsed/Refractory Philadelphia Negative CD19+ Acute Lymphoblastic Leukemia

Researchers

Presenter

  • David A Rizzieri

Principal Investigators

  • Jessica Leonard

  • Talha Badar

  • Franklin L. Chen

  • Bijal D. Shah

  • Zhiguo Li

Medical Centers

  • School of Medicine, Oregon Health and Science University, Portland, OR

  • Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL

  • Dept. of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC

  • Novant Health Oncology Specialists, Winston-Salem, NC

  • Department of Biostatistics and Bioinformatics, Duke University, Durham, NC

  • Division of Hematology and Oncology, Mayo Clinic, Florida

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 19

Drug/Treatment

  • Vincristine

  • Blinatumomab

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Adaptive

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved